XNYS
ZBH
Market cap17bUSD
Oct 08, Last price
88.88USD
1D
0.44%
1Q
-2.69%
Jan 2017
-11.29%
IPO
225.79%
Name
Zimmer Biomet Holdings Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zimmer Biomet Holdings, Inc., along with its various subsidiaries, is a prominent player in the global musculoskeletal healthcare industry, providing its specialized solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's comprehensive offerings span the design, manufacture, and commercialization of a wide array of innovative devices and products. These include orthopedic reconstructive solutions for knees and hips; S.E.T. offerings such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma interventions; spinal products encompassing diverse medical devices and surgical instruments; and specialized items for facial and cranial reconstruction. It also develops products designed to stabilize and fixate chest bones, critical for healing or reconstruction following open-heart surgery, trauma, or for correcting deformities. Additionally, Zimmer Biomet provides advanced dental products, comprising reconstructive implants, prosthetics, and regenerative materials, alongside essential robotic technologies, surgical tools, and bone cements. These extensive product lines and solutions are specifically engineered to address and treat patients afflicted by disorders or injuries impacting their bones, joints, and surrounding soft tissues. The company caters to a diverse clientele of healthcare professionals and institutions, including orthopedic, neuro, and oral surgeons, dentists, hospitals, as well as various distribution partners such as stocking distributors, healthcare dealers, agents, and large healthcare purchasing organizations. Established in 1927 and headquartered in Warsaw, Indiana, the entity previously known as Zimmer Holdings, Inc. underwent a rebranding in June 2015, adopting its current name, Zimmer Biomet Holdings, Inc.
Related entities
Subsidiaries (9)
zimmer biomet
Zimmer Biomet Austria GmbH
ZIMMER GMBH
ZIMMER INDIA PRIVATE LIMITED
ZIMMER, INC.
BIOMET GLOBAL SUPPLY CHAIN CENTER BV
Zimmer Luxembourg II S.à r.l
ZIMMER MANUFACTURING B.V.
ZIMMER ORTHOPEDICS MANUFACTURING LIMITED
Key people
Ivan Tornos
Chairman of the Board, President, Chief Executive Officer · since 2025
Suketu Upadhyay
Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain · since 2023
Robert Delps
President, Americas · since 2017
Kevin Thornal
Group President - Global Businesses, Americas · since 2025
Wilfred Van Zuilen
President - Europe, Middle East and Africa · since 2021
Sang Yi
Group President, Asia Pacific · since 2015
Lori Winkler
Chief Human Resources Officer, Senior Vice President · since 2021
Kristen Cardillo
Senior Vice President, Chief Communications Officer · since 2025
Senior Vice President, Chief Strategy, Innovation and Business Development Officer · since 2025
Chad Phipps
Senior Vice President, General Counsel, Secretary · since 2007
Paul Stellato
Chief Accounting Officer, Vice President, Controller · since 2022
David DeMartino
Senior Vice President - Investor Relations · since 2024
Lead Independent Director · since 2025
Betsy Bernard
Independent Director · since 2009
Independent Director · since 2008
Independent Director · since 2007
Independent Director · since 2018
Syed Jafry
Independent Director · since 2018
Independent Director · since 2021
Independent Director · since 2024
IPO date
Jul 25, 2001
Employees
18,000
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
345 East Main Street
Warsaw, IN 46580
US
Warsaw, IN 46580
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||